文献速递胰腺与胆道疾病消化道肿瘤与早癌消化内镜

全覆膜与部分覆膜自膨式金属支架用于远端恶性胆道梗阻姑息治疗的系统评价与Meta分析

Fully covered versus partially covered self-expandable metal stents for palliation of distal malignant biliary obstruction: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2023-10-07

该系统评价与Meta分析比较全覆膜与部分覆膜自膨式金属支架治疗远端恶性胆道梗阻,纳入62项研究(全覆膜组3327例,部分覆膜组2322例)。两组总不良事件率及各类不良事件率差异微小,但部分覆膜支架的支架通畅时间更长。

要点

  • 全覆膜与部分覆膜支架总不良事件率分别为12%与9.9%,差异微小。
  • 部分覆膜支架的通畅时间(369天)长于全覆膜支架(238天)。
  • 全覆膜支架的肿瘤内生率较低(0.5% vs 2.9%),但移位率较高(9.8% vs 4.3%)。

核心结论

  • 尽管存在相当大的异质性和较小的标准化差异,部分覆膜支架在所有分析中均显示比全覆膜支架更长的复发胆道梗阻时间,且不良事件率无其他差异,可能提出部分覆膜支架作为未来随机研究的標準对照和复发胆道梗阻作为主要结局。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Scopus和Cochrane数据库至2023年1月,纳入62项研究,全覆膜支架组3327例,部分覆膜支架组2322例,采用随机效应模型计算合并比例或均值。

主要发现

  • 全覆膜支架与部分覆膜支架的总不良事件率分别为12%与9.9%,各类特定不良事件率差异微小,包括胆囊炎(2.5% vs 2.6%)。
  • 在限制于前瞻性研究和不可切除疾病的亚分析中,全覆膜支架的复发胆道梗阻率为27.3%(95% CI 23.7-31.2,I²=35.34%),部分覆膜支架为25.3%(95% CI 20.2-30.7,I²=85.09%)。
  • 全覆膜支架的肿瘤内生率为0.5%,部分覆膜支架为2.9%(d值0.186-0.216),全覆膜支架的移位率为9.8%,部分覆膜支架为4.3%。
  • 全覆膜支架的复发胆道梗阻时间为238天(95% CI 191-286,I²=63.1%),部分覆膜支架为369天(95% CI 290-449,I²=71.9%,d值=0.116)。

关键数值与推荐

  • 全覆膜支架与部分覆膜支架的总不良事件率分别为12%与9.9%。
  • 全覆膜支架与部分覆膜支架的胆囊炎发生率分别为2.5%与2.6%。
  • 亚分析中全覆膜支架与部分覆膜支架的复发胆道梗阻率分别为27.3%(95% CI 23.7-31.2)与25.3%(95% CI 20.2-30.7)。
  • 全覆膜支架与部分覆膜支架的肿瘤内生率分别为0.5%与2.9%,移位率分别为9.8%与4.3%。
  • 全覆膜支架与部分覆膜支架的复发胆道梗阻时间分别为238天(95% CI 191-286)与369天(95% CI 290-449)。

临床怎么用

  • 作者认为,部分覆膜支架可能作为未来随机研究的標準对照,复发胆道梗阻时间可作为主要结局。

局限性

  • 原文报告存在相当大的异质性,全覆膜支架复发胆道梗阻时间I²=63.1%,部分覆膜支架I²=71.9%,亚分析中部分覆膜支架复发胆道梗阻率I²=85.09%。
  • 原文报告标准化差异较小,d值在0.116至0.216之间。
  • 原文提及未来需进行随机研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Self-expandable metal stents (SEMSs) are standardly used for distal malignant biliary obstruction (dMBO). Although data suggest that covered versus uncovered SEMSs increase the time to recurrent biliary obstruction (TRBO), no data are available for fully covered (FC) versus partially covered (PC) designs. METHODS: PubMed, Scopus, and Cochrane databases were screened up to January 2023 for studies concerning dMBO treated by an FC- or PC-SEMS and describing adverse events (AEs), recurrences, or TRBO for specific design subpopulations. Pooled proportions or means were calculated using a random-effects model. Several subanalyses were preplanned, including a subanalysis restricted to prospective studies and unresectable diseases. Heterogeneity and publication bias were explored. Standardized differences (d-values) were calculated between groups. RESULTS: From 1290 records, 62 studies (3327 using FC-SEMSs and 2322 using PC-SEMSs) were included. FC- versus PC-SEMSs showed negligible differences in the rate of total AEs (12% vs 9.9%) and all specific AEs, including cholecystitis (2.5% vs 2.6%). In a subanalysis restricted to prospective studies and unresectable diseases, the rate of RBO was comparable between FC-SEMSs (27.3% [95% confidence interval {CI}, 23.7-31.2], I2 = 35.34%) and PC-SEMSs (25.3% [95% CI, 20.2-30.7], I2 = 85.09%), despite small differences (d-values between .186 and .216) in the rate of ingrowth (.5% vs 2.9%) favoring FC-SEMSs and migration (9.8% vs 4.3%) favoring PC-SEMSs. TRBO was shorter for FC-SEMSs (238 days [95% CI, 191-286], I2 = 63.1%) versus PC-SEMSs (369 days [95% CI, 290-449], I2 = 71.9%; d-value = .116). CONCLUSIONS: Despite considerable heterogeneity and small standardized differences, PC-SEMSs consistently exhibited longer TRBO than FC-SEMSs across analyses, without any other differences in AE rates, potentially proposing PC-SEMSs as the standard comparator and TRBO as the primary outcome for future randomized studies on dMBO. (Clinical trial registration number: CRD42023393965.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Vanella G, Coluccio C, Cucchetti A, et al. Fully covered versus partially covered self-expandable metal stents for palliation of distal malignant biliary obstruction: a systematic review and meta-analysis. Gastrointest Endosc. 2023. PMID: 37813199. doi:10.1016/j.gie.2023.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。